Home | Business News | Browse by Publication | P | Pharma Marketletter

MHLW grants priority review for Bayer's Nexavar; approves Primovist.

Publication: Pharma Marketletter
Publication Date: 28-JAN-08
Format: Online
Delivery: Immediate Online Access

Article Excerpt
Japan's Ministry of Health, Labor and Welfare (MHLW) has granted German drugmaker Bayer priority review status for marketing authorization of its anticancer drug product Nexavar (sorafenib) for the treatment of hepatocellular carcinoma. In addition, the contrast agent Primovist (gadoxetic acid disodium) was also cleared in the Japan for the...

View this article FREE - Now for a Limited Time, try Goliath Business News
Free for 3 Days!



More articles from Pharma Marketletter
FDA asks CytRx to halt Ph II arimoclomol study., January 28, 2008

Looking for additional articles?
Search our database of over 3 million articles.

Looking for more in-depth information on this industry?
Search our complete database of Industry & Market reports by text, subject, publication name or publication date.

About Goliath
Whether you're looking for sales prospects, competitive information, company analysis or best practices in managing your organization, Goliath can help you meet your business needs.

Our extensive business information databases empower business professionals with both the breadth and depth of credible, authoritative information they need to support their business goals. Whether it be strategic planning, sales prospecting, company research or defining management best practices - Goliath is your leading source for accurate information.